

20. EMPLOYMENT BENEFIT LIABILITY CONTINUED

Analysis of employee benefit liabilities:

	GROUP		COMPANY	
	June 2017 R'000	June 2016 R'000	June 2017 R'000	June 2016 R'000
Current portion	86 233	106 777	4 500	–

21. REVENUE

	GROUP		COMPANY	
	June 2017 R'000	June 2016 R'000	June 2017 R'000	June 2016 R'000
Revenue from sale of goods*	1 069 435	748 477	–	–
Administration fees	1 385 844	1 230 288	–	–
Health risk management fees	929 411	805 104	–	–
Management fees	1 869	1 222	–	–
IT revenue and other	398 142	363 055	50	50
Revenue from performance of services	2 715 266	2 399 669	50	50
Total revenue	3 784 701	3 148 146	50	50

* This relates to sale of pharmaceutical products which resulted from the WAD healthcare assets acquisition in the 2016 financial year.

22. COST OF PHARMACEUTICAL PRODUCTS

	GROUP		COMPANY	
	June 2017 R'000	June 2016 R'000	June 2017 R'000	June 2016 R'000
Opening inventory	72 310	6 803	–	–
Purchases	837 800	653 711	–	–
Closing inventory	(73 376)	(72 310)	–	–
	836 734	588 204	–	–

This relates to sale of pharmaceutical products which resulted from the WAD healthcare assets acquisition in the 2016 financial year.